US FDA's Search For Meaning: Interpretation Of Regulatory Language Can Inspire Conflict In Drug Reviews
Executive Summary
The Pink Sheet's Drug Review Profile series illustrates the challenge of reconciling review realities and broad statutory directives.
You may also be interested in...
Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
In memo to then-Commissioner Califf during review of Sarepta's Exondys 51, Jenkins wrote that he was concerned about leaving OND in hands of CDER director upon his retirement.
US FDA's Device-Focused Patient Engagement AdComm Tackles Trial Challenges
FDA's new Patient Engagement Advisory Committee will discuss patient perspectives on device clinical trials at its first scheduled meeting.
FDA's 21st Century Cures Plan Gives Patient-Focused Drug Development A Boost
US agency will hold five workshops and develop seven guidance documents focused on patient input in the drug development and review process; since some guidance requirements under Cures law overlap with those in PDUFA VI commitment letter, most of the funding will come from user fees.